Adjuvant Pembrolizumab in Resected Stage III Melanoma
Adjuvant Pembrolizumab in Resected Stage III Melanoma
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
More information
Scope and Contents
Contents
To the Editor:
In the past 2 years, Eggermont et al. have reported the findings of two landmark trials of adjuvant immunotherapy for stage III melanoma: the European Organization for the Research and Treatment of Cancer (EORTC) 18071 trial of ipilimumab
1
and the EORTC 1325 trial of pembrolizumab (May 10 issue).
2
Both trials suggest...
Alternative Titles
Full title
Adjuvant Pembrolizumab in Resected Stage III Melanoma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2086258560
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2086258560
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMc1807505
